Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

High levels of lipoprotein (a)[Lp (a)], an apoB100-containing lipoprotein, are an independent
and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms …

Background Lipoprotein (a) is a presumed risk factor for atherosclerotic cardiovascular
disease. Olpasiran is a small interfering RNA that reduces lipoprotein (a) synthesis in the …

Compelling evidence supports a causal role for lipoprotein (a)(Lp (a)) in cardiovascular
disease. No pharmacotherapies directly targeting Lp (a) are currently available for clinical …

Disturbed cholesterol homeostasis plays critical roles in the development of multiple
diseases, such as cardiovascular diseases (CVD), neurodegenerative diseases and …

OP-EHEA191011_online 2313..2340 Page 1 Low-density lipoproteins cause atherosclerotic
cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus …

Despite their importance in disease and evolution, highly identical segmental duplications
(SDs) are among the last regions of the human reference genome (GRCh38) to be fully …

version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

Apolipoproteins are important structural components of plasma lipoproteins that influence
vascular biology and atherosclerotic disease pathophysiology by regulating lipoprotein …

Objective: Lp (a)(lipoprotein [a]) concentrations are associated with atherosclerotic
cardiovascular disease (ASCVD), and new therapies that enable potent and specific …